Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2011-06, Vol.127 (3), p.713-720 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 720 |
|---|---|
| container_issue | 3 |
| container_start_page | 713 |
| container_title | Breast cancer research and treatment |
| container_volume | 127 |
| creator | Cancello, G. Maisonneuve, P. Rotmensz, N. Viale, G. Mastropasqua, M. G. Pruneri, G. Montagna, E. Dellapasqua, S. Iorfida, M. Cardillo, A. Veronesi, P. Luini, A. Intra, M. Gentilini, O. Scarano, E. Goldhirsch, A. Colleoni, M. |
| description | Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 |
| doi_str_mv | 10.1007/s10549-011-1465-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00628286v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356142759</galeid><sourcerecordid>A356142759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-97e8e3270293011c35ab2b8c77681b077f87df8684f895f1de7744da10e7f16f3</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEomXhB3BBFoiPSqTYTuxJjqsKKNJKcFjOlpNMNq4Se2snRXvgv-MoS0sRyLItjZ95x_ORJM8ZPWeUwofAqMjLlDKWslyKFB4kp0xAlgJn8DA5pUxCKgsqT5InIVxRSkug5ePkhLNccMr5afLzm3c764IJxFjyww0YTzN2JAy678m7LRtM_X7LdNzVGbGuwdTiTo_mBonbo9dVj6TyqMNIam1r9KQ6EDMMk3WdCaOrO4wSUexAAvZYj9iQMFXjYY_hafKo1X3AZ8d7lXz_9HF7cZluvn7-crHepLUAMaYlYIEZB8rLLCZbZ0JXvCpqAFmwigK0BTRtIYu8LUrRsgYB8rzRjCK0TLbZKjlbdDvdq703g_YH5bRRl-uNmm2USl7wQt6wyL5d2L131xOGUQ0m1Nj32qKbgophKAeIX1klL_8ir9zkbUxEFVCwTFKQEXq1QDvdozK2daPX9Syp1pmQLOcgZqnzf1BxNXPxnMXWRPs9hzd_OHSo-7ELrp9G42y4D7IFrL0LwWN7mz-jap4itUyRioVV8xQpiD4vjolN1YDNrcfvsYnA6yOgQ2xt62PjTbjjcp4JxkXk-MKF-GR36O8q9P_ovwBFK9tf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878136076</pqid></control><display><type>article</type><title>Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Cancello, G. ; Maisonneuve, P. ; Rotmensz, N. ; Viale, G. ; Mastropasqua, M. G. ; Pruneri, G. ; Montagna, E. ; Dellapasqua, S. ; Iorfida, M. ; Cardillo, A. ; Veronesi, P. ; Luini, A. ; Intra, M. ; Gentilini, O. ; Scarano, E. ; Goldhirsch, A. ; Colleoni, M.</creator><creatorcontrib>Cancello, G. ; Maisonneuve, P. ; Rotmensz, N. ; Viale, G. ; Mastropasqua, M. G. ; Pruneri, G. ; Montagna, E. ; Dellapasqua, S. ; Iorfida, M. ; Cardillo, A. ; Veronesi, P. ; Luini, A. ; Intra, M. ; Gentilini, O. ; Scarano, E. ; Goldhirsch, A. ; Colleoni, M.</creatorcontrib><description>Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 < 14%); (ii) Luminal B (ER-positive and/or PgR-positive, HER2-positive and/or Ki-67 ≥ 14%); (iii) HER2-positive, both endocrine receptors absent; and (iv) Triple Negative. At multivariate analysis, women with the Triple Negative breast cancer subtype had an increased risk of loco-regional relapse (LRR) (Hazards Ratio (HR) 3.58; 95%CI: 1.40–9.13) and breast cancer related events (HR 2.18; 95%CI: 1.04–4.57). Overall, Luminal B subtype was not associated with a statistically significant increased risk of recurrence compared with Luminal A, while patients with Luminal B subtype tumours overexpressing HER2 had a 2 fold risk of reduced breast cancer related survival (BCS), but not an increased risk of LRR and distant metastases. Women with HER2 breast cancer subtype had a statistically significant increased risk of LRR (HR 4.53; 95%CI: 1.56–13.1), distant metastases and reduced BCS (HR 3.22; 95%CI: 1.44–7.18) and overall survival (HR 2.87; 95%CI: 1.05–7.89) when compared with the Luminal A subtype, at multivariate analysis. In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-011-1465-7</identifier><identifier>PMID: 21452022</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Biological and medical sciences ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer research ; Cancer therapies ; Clinical Trial ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Ki-67 Antigen ; Mammary gland diseases ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Oncology ; Prognosis ; Receptor, ErbB-2 - analysis ; Receptors, Estrogen - analysis ; Receptors, Progesterone - analysis ; Recurrence ; Risk factors ; Tumors ; Women</subject><ispartof>Breast cancer research and treatment, 2011-06, Vol.127 (3), p.713-720</ispartof><rights>Springer Science+Business Media, LLC. 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-97e8e3270293011c35ab2b8c77681b077f87df8684f895f1de7744da10e7f16f3</citedby><cites>FETCH-LOGICAL-c575t-97e8e3270293011c35ab2b8c77681b077f87df8684f895f1de7744da10e7f16f3</cites><orcidid>0000-0002-5309-4704</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-011-1465-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-011-1465-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24235125$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21452022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00628286$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Cancello, G.</creatorcontrib><creatorcontrib>Maisonneuve, P.</creatorcontrib><creatorcontrib>Rotmensz, N.</creatorcontrib><creatorcontrib>Viale, G.</creatorcontrib><creatorcontrib>Mastropasqua, M. G.</creatorcontrib><creatorcontrib>Pruneri, G.</creatorcontrib><creatorcontrib>Montagna, E.</creatorcontrib><creatorcontrib>Dellapasqua, S.</creatorcontrib><creatorcontrib>Iorfida, M.</creatorcontrib><creatorcontrib>Cardillo, A.</creatorcontrib><creatorcontrib>Veronesi, P.</creatorcontrib><creatorcontrib>Luini, A.</creatorcontrib><creatorcontrib>Intra, M.</creatorcontrib><creatorcontrib>Gentilini, O.</creatorcontrib><creatorcontrib>Scarano, E.</creatorcontrib><creatorcontrib>Goldhirsch, A.</creatorcontrib><creatorcontrib>Colleoni, M.</creatorcontrib><title>Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 < 14%); (ii) Luminal B (ER-positive and/or PgR-positive, HER2-positive and/or Ki-67 ≥ 14%); (iii) HER2-positive, both endocrine receptors absent; and (iv) Triple Negative. At multivariate analysis, women with the Triple Negative breast cancer subtype had an increased risk of loco-regional relapse (LRR) (Hazards Ratio (HR) 3.58; 95%CI: 1.40–9.13) and breast cancer related events (HR 2.18; 95%CI: 1.04–4.57). Overall, Luminal B subtype was not associated with a statistically significant increased risk of recurrence compared with Luminal A, while patients with Luminal B subtype tumours overexpressing HER2 had a 2 fold risk of reduced breast cancer related survival (BCS), but not an increased risk of LRR and distant metastases. Women with HER2 breast cancer subtype had a statistically significant increased risk of LRR (HR 4.53; 95%CI: 1.56–13.1), distant metastases and reduced BCS (HR 3.22; 95%CI: 1.44–7.18) and overall survival (HR 2.87; 95%CI: 1.05–7.89) when compared with the Luminal A subtype, at multivariate analysis. In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Clinical Trial</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Ki-67 Antigen</subject><subject>Mammary gland diseases</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Progesterone - analysis</subject><subject>Recurrence</subject><subject>Risk factors</subject><subject>Tumors</subject><subject>Women</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kk1v1DAQhiMEomXhB3BBFoiPSqTYTuxJjqsKKNJKcFjOlpNMNq4Se2snRXvgv-MoS0sRyLItjZ95x_ORJM8ZPWeUwofAqMjLlDKWslyKFB4kp0xAlgJn8DA5pUxCKgsqT5InIVxRSkug5ePkhLNccMr5afLzm3c764IJxFjyww0YTzN2JAy678m7LRtM_X7LdNzVGbGuwdTiTo_mBonbo9dVj6TyqMNIam1r9KQ6EDMMk3WdCaOrO4wSUexAAvZYj9iQMFXjYY_hafKo1X3AZ8d7lXz_9HF7cZluvn7-crHepLUAMaYlYIEZB8rLLCZbZ0JXvCpqAFmwigK0BTRtIYu8LUrRsgYB8rzRjCK0TLbZKjlbdDvdq703g_YH5bRRl-uNmm2USl7wQt6wyL5d2L131xOGUQ0m1Nj32qKbgophKAeIX1klL_8ir9zkbUxEFVCwTFKQEXq1QDvdozK2daPX9Syp1pmQLOcgZqnzf1BxNXPxnMXWRPs9hzd_OHSo-7ELrp9G42y4D7IFrL0LwWN7mz-jap4itUyRioVV8xQpiD4vjolN1YDNrcfvsYnA6yOgQ2xt62PjTbjjcp4JxkXk-MKF-GR36O8q9P_ovwBFK9tf</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Cancello, G.</creator><creator>Maisonneuve, P.</creator><creator>Rotmensz, N.</creator><creator>Viale, G.</creator><creator>Mastropasqua, M. G.</creator><creator>Pruneri, G.</creator><creator>Montagna, E.</creator><creator>Dellapasqua, S.</creator><creator>Iorfida, M.</creator><creator>Cardillo, A.</creator><creator>Veronesi, P.</creator><creator>Luini, A.</creator><creator>Intra, M.</creator><creator>Gentilini, O.</creator><creator>Scarano, E.</creator><creator>Goldhirsch, A.</creator><creator>Colleoni, M.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-5309-4704</orcidid></search><sort><creationdate>20110601</creationdate><title>Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes</title><author>Cancello, G. ; Maisonneuve, P. ; Rotmensz, N. ; Viale, G. ; Mastropasqua, M. G. ; Pruneri, G. ; Montagna, E. ; Dellapasqua, S. ; Iorfida, M. ; Cardillo, A. ; Veronesi, P. ; Luini, A. ; Intra, M. ; Gentilini, O. ; Scarano, E. ; Goldhirsch, A. ; Colleoni, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-97e8e3270293011c35ab2b8c77681b077f87df8684f895f1de7744da10e7f16f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Clinical Trial</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Ki-67 Antigen</topic><topic>Mammary gland diseases</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Progesterone - analysis</topic><topic>Recurrence</topic><topic>Risk factors</topic><topic>Tumors</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cancello, G.</creatorcontrib><creatorcontrib>Maisonneuve, P.</creatorcontrib><creatorcontrib>Rotmensz, N.</creatorcontrib><creatorcontrib>Viale, G.</creatorcontrib><creatorcontrib>Mastropasqua, M. G.</creatorcontrib><creatorcontrib>Pruneri, G.</creatorcontrib><creatorcontrib>Montagna, E.</creatorcontrib><creatorcontrib>Dellapasqua, S.</creatorcontrib><creatorcontrib>Iorfida, M.</creatorcontrib><creatorcontrib>Cardillo, A.</creatorcontrib><creatorcontrib>Veronesi, P.</creatorcontrib><creatorcontrib>Luini, A.</creatorcontrib><creatorcontrib>Intra, M.</creatorcontrib><creatorcontrib>Gentilini, O.</creatorcontrib><creatorcontrib>Scarano, E.</creatorcontrib><creatorcontrib>Goldhirsch, A.</creatorcontrib><creatorcontrib>Colleoni, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cancello, G.</au><au>Maisonneuve, P.</au><au>Rotmensz, N.</au><au>Viale, G.</au><au>Mastropasqua, M. G.</au><au>Pruneri, G.</au><au>Montagna, E.</au><au>Dellapasqua, S.</au><au>Iorfida, M.</au><au>Cardillo, A.</au><au>Veronesi, P.</au><au>Luini, A.</au><au>Intra, M.</au><au>Gentilini, O.</au><au>Scarano, E.</au><au>Goldhirsch, A.</au><au>Colleoni, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>127</volume><issue>3</issue><spage>713</spage><epage>720</epage><pages>713-720</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and M0 breast cancer according to four immunohistochemically defined tumour subtypes: (i) Luminal A (ER-positive, PgR-positive, HER2-negative and Ki-67 < 14%); (ii) Luminal B (ER-positive and/or PgR-positive, HER2-positive and/or Ki-67 ≥ 14%); (iii) HER2-positive, both endocrine receptors absent; and (iv) Triple Negative. At multivariate analysis, women with the Triple Negative breast cancer subtype had an increased risk of loco-regional relapse (LRR) (Hazards Ratio (HR) 3.58; 95%CI: 1.40–9.13) and breast cancer related events (HR 2.18; 95%CI: 1.04–4.57). Overall, Luminal B subtype was not associated with a statistically significant increased risk of recurrence compared with Luminal A, while patients with Luminal B subtype tumours overexpressing HER2 had a 2 fold risk of reduced breast cancer related survival (BCS), but not an increased risk of LRR and distant metastases. Women with HER2 breast cancer subtype had a statistically significant increased risk of LRR (HR 4.53; 95%CI: 1.56–13.1), distant metastases and reduced BCS (HR 3.22; 95%CI: 1.44–7.18) and overall survival (HR 2.87; 95%CI: 1.05–7.89) when compared with the Luminal A subtype, at multivariate analysis. In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>21452022</pmid><doi>10.1007/s10549-011-1465-7</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5309-4704</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2011-06, Vol.127 (3), p.713-720 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00628286v1 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Analysis Biological and medical sciences Biomarkers, Tumor Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer research Cancer therapies Clinical Trial Female Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Ki-67 Antigen Mammary gland diseases Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Oncology Prognosis Receptor, ErbB-2 - analysis Receptors, Estrogen - analysis Receptors, Progesterone - analysis Recurrence Risk factors Tumors Women |
| title | Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A18%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20in%20women%20with%20small%20(T1mic,T1a,T1b)%20node-negative%20operable%20breast%20cancer%20by%20immunohistochemically%20selected%20subtypes&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Cancello,%20G.&rft.date=2011-06-01&rft.volume=127&rft.issue=3&rft.spage=713&rft.epage=720&rft.pages=713-720&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-011-1465-7&rft_dat=%3Cgale_hal_p%3EA356142759%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=878136076&rft_id=info:pmid/21452022&rft_galeid=A356142759&rfr_iscdi=true |